Specific method validation and sample analysis approaches for biocomparability studies of denosumab addressing method and manufacture site changes.
Manufacturing changes during a biological drug product life cycle occur often; one common change is that of the manufacturing site. Comparability studies may be required to ensure that the changes will not affect the pharmacokinetic properties of the drug. In addition, the bioanalytical method for sample analysis may evolve during the course of drug development. This paper illustrates the scenario of both manufacturing and bioanalytical method changes encountered during the development of denosumab, a fully human monoclonal antibody which inhibits bone resorption by targeting RANK Ligand. Here, we present a rational approach to address the bioanalytical method changes and provide considerations for method validation and sample analysis in support of biocomparability studies. An updated and improved ELISA method was validated, and its performance was compared to the existing method. The analytical performances, i.e., the accuracy and precision of standards and validation samples prepared from both manufacturing formulation lots, were evaluated and found to be equivalent. One of the lots was used as the reference standard for sample analysis of the biocomparability study. This study was sufficiently powered using a parallel design. The bioequivalence acceptance criteria for small molecule drugs were adopted. The pharmacokinetic parameters of the subjects dosed with both formulation lots were found to be comparable.
Department of Pharmacokinetic and Drug Metabolism, Amgen Inc., One Amgen Center Dr, Thousand Oaks, CA 91320, USA. ramakp@amgen.com
Ramak
R
Pourvasei
Ed
E
Lee
Michael
M
Eschenberg
Vimal
V
Patel
Chris
C
Macaraeg
Kinnari
K
Pandya
Judy
J
Shih
Mark
M
Ma
Jean W
JW
Lee
Binodh
B
DeSilva
D061067:Antibodies, Monoclonal, Humanized / Q000032:analysis* / Q000493:pharmacokinetics; D000069448:Denosumab; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods*; D006801:Humans; D053245:RANK Ligand / Q000037:antagonists & inhibitors*; D011933:Reagent Kits, Diagnostic
D061067:Antibodies, Monoclonal, Humanized; D053245:RANK Ligand; D011933:Reagent Kits, Diagnostic; D000069448:Denosumab